{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T16:00:41Z","timestamp":1790438441078,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019265","name":"Yuhan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["RS-2024-00439277"],"award-info":[{"award-number":["RS-2024-00439277"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.intimp.2026.117275","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T11:59:41Z","timestamp":1786622381000},"page":"117275","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A multiple ascending dose, phase1b study to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of lesigercept, a long-acting IgETrap-Fc fusion protein, in participants with atopy or allergic diseases"],"prefix":"10.1016","volume":"188","author":[{"given":"You Sook","family":"Cho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Min","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sook Young","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sae-Hoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Young","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyo Hyun","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Lip","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang Won","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith Maria","family":"Ertle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeon-Ju","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujin","family":"Sim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bomin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jungwook","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su Kyung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Hyung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myoung Ho","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hae-Sim","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.intimp.2026.117275_bb0005","doi-asserted-by":"crossref","DOI":"10.1111\/imr.70057","article-title":"IgE in allergic diseases","volume":"334","author":"Greene","year":"2025","journal-title":"Immunol. Rev."},{"issue":"5","key":"10.1016\/j.intimp.2026.117275_bb0010","doi-asserted-by":"crossref","first-page":"531","DOI":"10.4168\/aair.2025.17.5.531","article-title":"An overview of chronic spontaneous urticaria: diagnosis, management, and treatment","volume":"17","author":"Tbakhi","year":"2025","journal-title":"Allergy Asthma Immunol. Res."},{"issue":"3","key":"10.1016\/j.intimp.2026.117275_bb0015","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/all.15090","article-title":"The international EAACI\/GA2LEN\/EuroGuiDerm\/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria","volume":"77","author":"Zuberbier","year":"2022","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.intimp.2026.117275_bb0020","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jaad.2014.03.023","article-title":"Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies","volume":"71","author":"Eichenfield","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"issue":"12","key":"10.1016\/j.intimp.2026.117275_bb0025","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1007\/s13555-022-00819-6","article-title":"Burden of atopic dermatitis in adults and adolescents: a systematic literature review","volume":"12","author":"Fasseeh","year":"2022","journal-title":"Dermatol. Ther. (Heidelb.)"},{"issue":"6","key":"10.1016\/j.intimp.2026.117275_bb0030","doi-asserted-by":"crossref","first-page":"419","DOI":"10.5021\/ad.21.239","article-title":"Assessment of disease severity and quality of life in patients with atopic dermatitis from South Korea","volume":"34","author":"Son","year":"2022","journal-title":"Ann. Dermatol."},{"issue":"6","key":"10.1016\/j.intimp.2026.117275_bb0035","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/bjd.14768","article-title":"Updosing nonsedating antihistamines in patients with chronic spontaneous urticaria: a systematic review and meta-analysis","volume":"175","author":"Guillen-Aguinaga","year":"2016","journal-title":"Br. J. Dermatol."},{"issue":"2","key":"10.1016\/j.intimp.2026.117275_bb0040","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.alit.2020.01.004","article-title":"Roles of omalizumab in various allergic diseases","volume":"69","author":"Okayama","year":"2020","journal-title":"Allergol. Int."},{"issue":"1","key":"10.1016\/j.intimp.2026.117275_bb0045","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41467-019-13815-w","article-title":"The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab","volume":"11","author":"Gasser","year":"2020","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.intimp.2026.117275_bb0050","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.jaip.2014.03.010","article-title":"Omalizumab in asthma: an update on recent developments","volume":"2","author":"Humbert","year":"2014","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"1","key":"10.1016\/j.intimp.2026.117275_bb0055","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jaci.2013.05.013","article-title":"Omalizumab in patients with symptomatic chronic idiopathic\/spontaneous urticaria despite standard combination therapy","volume":"132","author":"Kaplan","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2026.117275_bb0060","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/all.13302","article-title":"Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma","volume":"73","author":"Casale","year":"2018","journal-title":"Allergy"},{"issue":"11","key":"10.1016\/j.intimp.2026.117275_bb0065","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1007\/s13555-023-01040-9","article-title":"Omalizumab for patients with chronic spontaneous urticaria: a narrative review of current status","volume":"13","author":"Casale","year":"2023","journal-title":"Dermatol. Ther. (Heidelb.)"},{"issue":"3","key":"10.1016\/j.intimp.2026.117275_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2021.100519","article-title":"Targeting immunoglobulin E in atopic dermatitis: a review of the existing evidence","volume":"14","author":"Wollenberg","year":"2021","journal-title":"World Allergy Organ. J."},{"issue":"3","key":"10.1016\/j.intimp.2026.117275_bb0075","doi-asserted-by":"crossref","first-page":"207","DOI":"10.4168\/aair.2018.10.3.207","article-title":"Significance of skin barrier dysfunction in atopic dermatitis","volume":"10","author":"Kim","year":"2018","journal-title":"Allergy Asthma Immunol. Res."},{"issue":"5","key":"10.1016\/j.intimp.2026.117275_bb0080","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/s41423-023-00992-4","article-title":"The translational revolution in atopic dermatitis: the paradigm shift from pathogenesis to treatment","volume":"20","author":"Facheris","year":"2023","journal-title":"Cell. Mol. Immunol."},{"issue":"10","key":"10.1016\/j.intimp.2026.117275_bb0085","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1016\/j.jid.2023.01.040","article-title":"IgE depletion with ligelizumab does not significantly improve clinical symptoms in patients with moderate-to-severe atopic dermatitis","volume":"143","author":"Bangert","year":"2023","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.intimp.2026.117275_bb0090","doi-asserted-by":"crossref","unstructured":"Su K\u00fc\u00e7\u00fck, \u00d6., Y\u00fccel, M.B., Clinical and molecular aspects of managing chronic spontaneous urticaria: identifying endotypes, phenotypes, and determinants of treatment response and resistance, Front. Allergy Volume 6\u20132025 (2026).","DOI":"10.3389\/falgy.2025.1706705"},{"key":"10.1016\/j.intimp.2026.117275_bb0095","unstructured":"US Food and Drug Administration, XOLAIR: Full Prescribing Information, 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/103976s5245lbl.pdf. (Accessed 2 March 2026."},{"issue":"1","key":"10.1016\/j.intimp.2026.117275_bb0100","doi-asserted-by":"crossref","first-page":"5669","DOI":"10.1038\/s41467-022-33176-1","article-title":"Combined IgE neutralization and Bifidobacterium longum supplementation reduces the allergic response in models of food allergy","volume":"13","author":"An","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2026.117275_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.111706","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of YH35324, a novel long-acting high-affinity IgE(trap)-fc protein in subjects with atopy: results from the first-in-human study","volume":"130","author":"Ye","year":"2024","journal-title":"Int. Immunopharmacol."},{"issue":"3","key":"10.1016\/j.intimp.2026.117275_bb0110","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/DER.0000000000000895","article-title":"The eczema area and severity index-a practical guide","volume":"33","author":"Hanifin","year":"2022","journal-title":"Dermatitis"},{"issue":"1","key":"10.1016\/j.intimp.2026.117275_bb0115","first-page":"23","article-title":"Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis","volume":"186","author":"European Task Force on Atopic Dermatitis","year":"1993","journal-title":"Dermatology"},{"issue":"3","key":"10.1016\/j.intimp.2026.117275_bb0120","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.jaad.2020.04.104","article-title":"The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): the development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis","volume":"83","author":"Simpson","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"issue":"4","key":"10.1016\/j.intimp.2026.117275_bb0125","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/bjd.17744","article-title":"Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis","volume":"181","author":"Yosipovitch","year":"2019","journal-title":"Br. J. Dermatol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117275_bb0130","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/jdv.16846","article-title":"Measurement properties of the product of investigator\u2019s global assessment and body surface area in children and adults with atopic dermatitis","volume":"35","author":"Silverberg","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"6","key":"10.1016\/j.intimp.2026.117275_bb0135","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1185\/030079903125002171","article-title":"Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma","volume":"19","author":"Hochhaus","year":"2003","journal-title":"Curr. Med. Res. Opin."},{"issue":"1","key":"10.1016\/j.intimp.2026.117275_bb0140","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.anai.2021.03.023","article-title":"Serum-free immunoglobulin E: a useful biomarker of atopy and type 2 asthma in adults with asthma","volume":"127","author":"Woo","year":"2021","journal-title":"Ann. Allergy Asthma Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117275_bb0145","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1365-2125.2009.03401.x","article-title":"Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma","volume":"68","author":"Lowe","year":"2009","journal-title":"Br. J. Clin. Pharmacol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926011215?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926011215?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T15:31:46Z","timestamp":1790436706000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576926011215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":29,"alternative-id":["S1567576926011215"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2026.117275","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A multiple ascending dose, phase1b study to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of lesigercept, a long-acting IgETrap-Fc fusion protein, in participants with atopy or allergic diseases","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2026.117275","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"117275"}}